A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Males aged 18-60 years and females aged 18-75 years at Screening.
• Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.
⁃ AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria
Locations
Other Locations
Australia
Coorparoo
RECRUITING
Coorparoo
St Leonards
NOT_YET_RECRUITING
Saint Leonards
South Yarra
NOT_YET_RECRUITING
South Yarra
New Zealand
Auckland
NOT_YET_RECRUITING
Auckland
Christchurch
NOT_YET_RECRUITING
Christchurch
Palmerston North
NOT_YET_RECRUITING
Palmerston North
Contact Information
Primary
Support Officer
recruitment@clinibase.com
+61 3 7050 1941
Time Frame
Start Date: 2025-10-23
Estimated Completion Date: 2027-03-10
Participants
Target number of participants: 32
Treatments
Active_comparator: FB102
Participants will receive FB102.
Placebo_comparator: Placebo
Matching placebo
Related Therapeutic Areas
Sponsors
Leads: Forte Biosciences, Inc.